POLARIS-2: Study of Olverembatinib (HQP1351) in Patients With CP-CML

Condition: Chronic Myeloid Leukemia

Sponsor: Ascentage Pharma Group Inc.

Full Title
Protocol HQP1351CG301: A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With Chronic Phase Chronic Myeloid Leukemia

Study Treatment
Third-generation BCR-ABL1 tyrosine kinase inhibitor Olverembatinib vs bosutinib

Eligibility/Info
Eligible patient must have chronic phase chronic myeloid leukemia without a history of accelerated or blastic phase.
Part A: Treatment with at least two prior TKIs and confirmed absence of T315I and V229L mutations
Part B: Confirmed presence of T315I mutation, prior treatment with at least 1 TKI, and lack of other effective/tolerable therapies

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Nostrand Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage